ACTIVE

K5 Therapeutics

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result261,7 k €+39,3 %over 1 year
Gross margin2,6 M €+42,6 %over 1 year
Equity3 M €+9,7 %over 1 year
Workforce17,8 ETP+31,9 %over 1 year

Identity

Source · BCE/KBO

K5 Therapeutics is a Private limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven. It employs on average 17,8 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0757.718.072
Incorporation
02/11/2020
Legal form
Private limited company
Registered office
Gaston Geenslaan 3
3001 Leuven · FlandreSee on map
Contributed capital
2 362 400,00 €
Latest accounts
31/12/2025
Average workforce
17,8 ETP
Joint committees (1)
  • 207
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 5 filings

Trend over 5 financial years

20252024202320222021
Income statement
Gross margin2,6 M €1,8 M €1,4 M €1,2 M €-685,4 k €
EBITDA459,9 k €358,6 k €249 k €903,2 k €-727,4 k €
Operating result258,2 k €166,8 k €121,2 k €894,9 k €-837,4 k €
Net result261,7 k €187,9 k €124,3 k €885,7 k €-862,9 k €
Balance sheet
Equity3 M €2,7 M €2,5 M €2,4 M €1,5 M €
Total assets3,6 M €3,3 M €3,2 M €2,9 M €1,5 M €
Cash1 M €416,6 k €112 k €73,3 k €220,6 k €
Debts497,2 k €560,5 k €699,3 k €523,2 k €23,3 k €
Other
Workforce17,8 ETP13,5 ETP10,6 ETP2,7 ETP0,8 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active

Active mandates

DirectorMandates in this companyPeriod
Anders Hinsby
Directorsince 16/07/2021
Jakob Busch-Petersen
Directorsince 16/07/2021
Rita Balice Gordon
Directorsince 16/07/2021

Other companies at this address

Gaston Geenslaan 3 3001 Leuven
CompanyCBE no.
AstriVax Therapeutics● Active
0787.990.881
AUGUSTINE THERAPEUTICS● Active
0722.705.230
COULTREON BIOPHARMA● Active
1019.429.814
Metaptys● Active
0554.664.311
Montis Biosciences● Active
0730.979.429
Perseus Biomics● Active
0650.946.412
QUOMAK● Active
0448.488.111
ReWind Therapeutics● Active
0682.626.216
Stichting Administratiekantoor Coultreon● Active
1040.853.946
Tavira Therapeutics● Active
0802.591.262
VEDRA THERAPEUTICS● Active
1039.565.628

Full financial information

Source · NBB
20252024202320222021
Type of accountAbridged modelAbridged modelAbridged modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202202/11/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/2021
Length of the financial year12 months12 months12 months12 months14 months
Filing date11/06/202624/06/202526/06/202407/07/202328/07/2022
General meeting10/06/202611/06/202512/06/202426/06/202317/06/2022
Currency of the financial yearEUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 5 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202510/06/202611/06/2026DutchPDF
Abridged model31/12/202411/06/202524/06/2025DutchPDF
Abridged model31/12/202312/06/202426/06/2024DutchPDF
Abridged model31/12/202226/06/202307/07/2023DutchPDF
Abridged model31/12/202117/06/202228/07/2022DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active

Active mandates

DirectorMandates in this companyPeriod
Anders Hinsby
Directorsince 16/07/2021
Jakob Busch-Petersen
Directorsince 16/07/2021
Rita Balice Gordon
Directorsince 16/07/2021

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Registered office22/11/2022
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Registered office20/07/2022
    MAATSCHAPPELIJKE ZETEL
    PDF
  • Mandates20/07/2021
    DIVERSEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates14/07/2021
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - ONTSLAGEN - BENOEMINGEN
    PDF
  • Other20/05/2021
    DIVERSEN
    PDF
  • Mandates29/12/2020
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Other04/11/2020
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings5 filings
Mandates
Rita Balice Gordon
Jakob Busch-Petersen
Anders Hinsby
2020202120222023202420252026
K5 Therapeutics
Gaston Geenslaan 3, 3001 Heverlee
Director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Gaston Geenslaan 3, 3001 HeverleeCurrent
accounts 2022 → 2025
Accounts 2025 · 2026-00153879
Brusselsesteenweg 11, 1860 Meise
accounts 2021
Accounts 2021 · 2022-20238149

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
K5 TherapeuticsCurrent
accounts 2021 → 2025
Accounts 2025 · 2026-00153879

Events

  1. 2025
    Annual accounts 2025261,7 k €↑
  2. 2024
    Annual accounts 2024187,9 k €↑
  3. 2023
    Annual accounts 2023124,3 k €↓
  4. 2022
    Annual accounts 2022885,7 k €↑
  5. 2021
    Annual accounts 2021-862,9 k €
  6. 02/11/2020
    IncorporationPrivate limited company